☆ 4.4 Article

RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma

CLINICAL LUNG CANCER (2018)

期刊

CLINICAL LUNG CANCER

卷 19, 期 5, 页码 E811-E814

出版社

CIG MEDIA GROUP, LP

DOI: 10.1016/j.cllc.2018.06.005

关键词

Advanced; Biologic therapy; First line; TC; TET

类别

Oncology

资金

Italian Medicines Agency [AIFA-2016-02364595]

向作者/读者索取更多资源

Protocol

Reagent

摘要

Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The association of chemotherapy and antiangiogenic agents in the first-line setting has never been investigated in this very rare cancer. However, preclinical and clinical evidence has suggested that inhibition of angiogenesis could be beneficial. The RELEVENT trial is a multicenter, open-label, single-arm, phase II study aimed at investigating the activity and safety of ramucirumab combined with paclitaxel and carboplatin in chemotherapy-naive patients affected by thymic carcinoma or B3 thymoma with area of carcinoma. The primary endpoint of the trial is the overall response rate. Progression-free survival, overall survival, and safety are secondary endpoints. Patient-reported outcomes will be collected at each visit. The mutational status of a subset of genes, polymorphisms, and selected micro-RNA expression will be evaluated. (C) 2018 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Editorial Material Oncology

JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma

Shun Yamamoto, Ken Kato

Summary: The phase III JUPITER-6 trial demonstrated that toripalimab plus chemotherapy outperformed chemotherapy alone in terms of progression-free survival and overall survival for previously untreated patients with advanced esophageal squamous cell carcinoma. This provides solid evidence that immune checkpoint inhibitors play a key role in the first-line treatment of advanced esophageal squamous cell carcinoma.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer

Patrick Neven, Stephen R. D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva-Maria Grischke, PierFranco Conte, Yi Lu, Nadine Haddad, Karla C. Hurt, Antonio Llombart-Cussac, George W. Sledge

Summary: Abemaciclib plus fulvestrant demonstrated significant improvements in PFS and OS compared to placebo plus fulvestrant in HR+, HER2(-) advanced breast cancer patients in both first- and second-line treatment subgroups. The benefits were particularly pronounced in patients with primary resistance to endocrine therapy and visceral disease.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma

Luca Ielasi, Francesco Tovoli, Matteo Tonnini, Bernardo Stefanini, Raffaella Tortora, Giulia Magini, Rodolfo Sacco, Tiziana Pressiani, Franco Trevisani, Ingrid Garajova, Fabio Piscaglia, Alessandro Granito

Summary: This study aimed to evaluate the prognostic role of different sites of metastases in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. The results showed that lymph nodes and lung metastases were associated with worse survival rates and treatment response, while bone and adrenal gland metastases did not significantly impact prognosis. Therefore, targeted treatment strategies should be considered for different metastatic sites.

CANCERS (2023)

添加到收藏夹

Review Oncology

First line treatment of BRAF mutated advanced melanoma: Does one size fit all?

Federica Giugliano, Edoardo Crimini, Paolo Tarantino, Paola Zagami, Jacopo Uliano, Chiara Corti, Dario Trapani, Giuseppe Curigliano, Paolo A. Ascierto

Summary: Immunotherapy and targeted therapy have revolutionized the prognosis of patients with metastatic melanoma carrying BRAF-V600 mutation. Multiple combinations of BRAF/MEK inhibitors and immune-checkpoint inhibitors have shown promising efficacy in untreated patients, with ongoing studies exploring novel treatment strategies.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Article Immunology

First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study

Ziqi Ye, Yanfang Zhang, Jie Chen, Xiaoting Wang, Yun Hong, Qingwei Zhao

Summary: This study assessed the impact of PD-1 inhibitors combination therapy on the survival of patients with advanced cholangiocarcinoma. The results demonstrated that this approach has promising efficacy and manageable adverse events, making it a first-line treatment for advanced cholangiocarcinoma in real-world settings.

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

添加到收藏夹

Article Oncology

Optimizing First-Line Therapy for Advanced- Stage Classic Hodgkin Lymphoma

Ranjana H. Advani

Summary: The goal of first-line therapy in classic Hodgkin lymphoma is to balance risk versus benefit to the individual while increasing efficacy and reducing toxicity. The ABVD regimen is well tolerated but slightly less effective, while BV-AVD falls between ABVD and escalated BEACOPP on the cure/morbidity scale. In patients with interim PET-negative cHL, de-escalating therapy does not impact overall survival.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer

Choong-kun Lee, Sun Young Rha, Hyo Song Kim, Minkyu Jung, Beodeul Kang, Jingmin Che, Woo Sun Kwon, Sejung Park, Woo Kyun Bae, Dong-Hoe Koo, Su-Jin Shin, Hyunki Kim, Hei-Cheul Jeung, Dae Young Zang, Sang Kil Lee, Chung Mo Nam, Hyun Cheol Chung

Summary: This study evaluated the efficacy and safety of a quadruplet regimen as first-line therapy for unresectable or metastatic HER2-positive advanced gastric cancer. The results showed durable efficacy and safety for patients treated with this regimen.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Review Medicine, General & Internal

First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy

Emilio Francesco Giunta, Alfredo Addeo, Alessio Rizzo, Giuseppe Luigi Banna

Summary: This review discusses the survival benefit of adding immune checkpoint inhibitors to first-line standard chemotherapy in advanced SCLC patients, based on the data from three phase III randomized clinical trials. It also analyzes unresolved issues and the future of SCLC first-line therapy management.

FRONTIERS IN MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia

Charlotte A. Bradbury, Julie Pell, Quentin Hill, Catherine Bagot, Nichola Cooper, Jenny Ingram, Katie Breheny, Rebecca Kandiyali, Rachel Rayment, Gillian Evans, Kate Talks, Ian Thomas, Rosemary Greenwood

Summary: In a multicenter, open-label, randomized trial on patients with immune thrombocytopenia, 91.5% of patients who received mycophenolate mofetil plus glucocorticoids had platelet levels above 100,000 per microliter, compared to 63.9% of patients who received glucocorticoids only. Quality-of-life measures of physical function and fatigue were worse in the mycophenolate mofetil group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Dermatology

Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS)

Clarisse Marcombes, Laetitia Penso, Alain Weill, Rosemary Dray-Spira, Mahmoud Zureik, Emilie Sbidian

Summary: This study compared the long-term persistence of different biologics in psoriasis treatment. It found that as a second-line treatment, IL-23 inhibitors had longer persistence compared to TNF inhibitors, IL-17 inhibitors, and IL-12/IL-23 inhibitors. The choice of first-line treatment also affected the persistence of second-line treatment.

BRITISH JOURNAL OF DERMATOLOGY (2023)

添加到收藏夹

Review Oncology

Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis

Richard Adams, Kaitlyn Goey, Benoist Chibaudel, Miriam Koopman, Cornelis Punt, Dirk Arnold, Axel Hinke, Susanna Hegewisch-Becker, Aimery de Gramont, Roberto Labianca, Eduardo Diaz Rubio, Kjell Magne Tveit, Harpreet Wasan, Richard Kaplan, Louise Brown, Tim Maughan, David Fisher

Summary: The individual patient data meta-analysis showed that intermittent chemotherapy strategies for advanced colorectal cancer did not lead to inferior overall survival compared to continuous chemotherapy, regardless of whether it was a maintenance or complete break strategy. Thrombocytosis was confirmed as a marker of poor prognosis in aCRC, but was not predictive of poor outcome in patients treated with intermittent therapy.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun, Lin Shen, Manish A. Shah, Peter Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean-Philippe Metges, Zhigang Li, Sung-Bae Kim, Byoung Chul Cho, Wasat Mansoor, Shau-Hsuan Li, Patrapim Sunpaweravong, Maria Alsina Maqueda, Eray Goekkurt, Hiroki Hara, Luis Antunes, Christos Fountzilas, Akihito Tsuji, Victor Castro Oliden, Qi Liu, Sukrut Shah, Pooja Bhagia, Ken Kato

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes

Jiun-Long Wang, Yi-Ting Tsai, Ching-Heng Lin, Abdulkadir Cidem, Theresa Staniczek, Gary Ro-Lin Chang, Chih-Ching Yen, Wei Chen, Kowit-Yu Chong, Chuan-Mu Chen

Summary: This study looked at the real-world use of metformin in combination with pemetrexed-based platinum doublets as a first-line treatment for diabetic patients with advanced lung adenocarcinoma. The results showed that the metformin-user group had a significant survival benefit, especially for those with a daily dose >= 1500 mg and a cumulative DDD >= 21. Larger randomized clinical trials are needed to further investigate the antitumor effects of metformin in advanced lung adenocarcinoma.

BIOMOLECULES (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean-Christophe Pignon, Miriam Ficial, Osvaldo Aren Frontera, Saby George, Thomas Powles, Frede Donskov, Michael R. Harrison, Philippe Barthelemy, Scott S. Tykodi, Judit Kocsis, Alain Ravaud, Jeronimo R. Rodriguez-Cid, Sumanta K. Pal, Andre M. Murad, Yuko Ishii, Shruti Shally Saggi, M. Brent McHenry, Brian Rini

Summary: This study analyzed the efficacy of NIVO+IPI versus sunitinib in patients with advanced renal cell carcinoma with sarcomatoid features, showing that NIVO+IPI provided long-term survival, response, and complete response benefits, particularly in patients with intermediate/poor-risk disease.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial

Xinni Chen, Shukui Qin, Shanzhi Gu, Zhenggang Ren, Zhendong Chen, Jianping Xiong, Ying Liu, Zhiqiang Meng, Xiao Zhang, Linna Wang, Xiaojing Zhang, Jianjun Zou

Summary: The study evaluated the combination of camrelizumab and chemotherapy as a first-line treatment for advanced BTC, showing promising efficacy and tolerability in Chinese patients, suggesting the need for further phase 3 trials.

INTERNATIONAL JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Use of PEAK PlasmaBlade in implant-based breast reconstruction and radiotherapy: new strategy to reduce complications

Laura Sala, Stefano Bonomi, Alessandra Fabbri, Chiara Maura Ciniselli, Annalisa Bardelli, Paolo Verderio, Giancarlo Pruneri, Umberto Cortinovis

Summary: This study investigated the use of the PEAK PlasmaBlade and acellular dermal matrix Veritas in implant-based breast reconstruction in the setting of radiotherapy. The results showed that this approach could lead to lower complication rates and higher levels of patient and surgeon satisfaction.

TUMORI JOURNAL (2023)

添加到收藏夹

Article Oncology

Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection

Nicla La Verde, Agostino Riva, Maria Silvia Cona, Arianna Gabrieli, Monica Cattaneo, Cinzia Fasola, Giuseppe Lipari, Claudia De Stradis, Valentina Favorito, Benedetta Lombardi Stocchetti, Davide Chizzoniti, Alice Covizzi, Eliana Rulli, Francesca Galli, Lorenzo Ruggieri, Anna Gambaro, Sabrina Ferrario, Davide Dalu, Maciej S. Tarkowski

Summary: This study evaluated the immunogenicity of mRNA vaccines in solid cancer patients, specifically those with or without previous exposure to SARS-CoV-2. The results showed that cancer patients previously exposed to the virus had similar vaccine response compared to healthy individuals, while clinical variables of immune frailty negatively affected the humoral immune response to vaccination.

INTERNATIONAL JOURNAL OF CANCER (2023)

添加到收藏夹

Review Oncology

Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts

Silvia Stacchiotti, Hans Roland Duerr, Inga-Marie Schaefer, Klaus Woertler, Rick Haas, Annalisa Trama, Augusto Caraceni, Jyoti Bajpai, Giacomo Giulio Baldi, Nicholas Bernthal, Jean-Yves Blay, Kjetil Boye, Javier-Martin Broto, Wei-Wu Tom Chen, Paolo Angelo Dei Tos, Jayesh Desai, Stephan Emhofer, Mikael Eriksson, Alessandro Gronchi, Hans Gelderblom, Jendrik Hardes, Wolfgang Hartmann, John Healey, Antoine Italiano, Robin L. Jones, Akira Kawai, Andreas Leithner, Herbert Loong, Eric Mascard, Carlo Morosi, Nadine Otten, Emanuela Palmerini, Shreyaskumar R. Patel, Peter Reichardt, Brian Rubin, Piotr Rutkowski, Claudia Sangalli, Kathrin Schuster, Beatrice M. Seddon, Morena Shkcodra, Eric L. Staals, William Tap, Matt van de Rijn, Kirsten van Langevelde, Filip M. M. Vanhoenacker, Andrew Wagner, Lisette Wiltink, Sydney Stern, Michiel Van de Sande, Sebastian Bauer

Summary: Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive tumor that arises from the joints, bursa, and tendon sheaths. There are two types of TGCT: nodular and diffuse, with the former exhibiting a slow disease course and the latter showing locally aggressive behavior. Although not life-threatening, TGCT can cause chronic pain and negatively impact function and quality of life. CSFR1 inhibitors are effective in treating TGCT but are not widely available. The lack of guidelines and uncertainty in selecting appropriate therapy lead to inconsistent adoption of new treatments and suboptimal outcomes for patients. A global consensus meeting was held in June 2022 to develop evidence-based recommendations for the optimal management of TGCT.

CANCER TREATMENT REVIEWS (2023)

添加到收藏夹

Article Oncology

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

N. Colombo, A. Gadducci, J. Sehouli, E. Rulli, J. Maeenpaeae, C. Sessa, A. Montes, N. B. Ottevanger, R. Berger, I. Vergote, M. B. D'Incalci, C. Churruca Galaz, R. Chekerov, G. B. Nyvang, S. Riniker, R. Herbertson, R. Fossati, M. P. Barretina-Ginesta, M. Deryal, M. R. Mirza, E. Biagioli, M. Iglesias, G. Funari, M. Romeo, G. Tasca, B. Pardo, G. Tognon, M. J. Rubio-Perez, A. DeCensi, U. De Giorgi, P. Zola, P. Benedetti Panici, M. Aglietta, V. Arcangeli, C. Zamagni, A. Bologna, A. Westermann, V. Heinzelmann-Schwarz, I. Tsibulak, P. Wimberger, A. Poveda

Summary: This trial aimed to investigate whether treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). The results showed that TP did not significantly improve OS in patients with a TFIp of 6-12 months, but it remains an effective treatment for patients suffering from persistent platinum toxicities.

BRITISH JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Increased incidence of rare cancers and varied age distributions by cancer group: A population-based cancer registry study in Hiroshima Prefecture, Japan

Hiromi Sugiyama, Manami Konda, Kumiko Saika, Annalisa Trama, Tomohiro Matsuda

Summary: This study aimed to describe the burden and changing time trends of rare cancers in Hiroshima, Japan. The proportion of rare cancer families to total cancers was stable, but the incidence rates for head and neck cancers, neuroendocrine tumors, and hematological cancers significantly increased. This suggests that increased knowledge, improved diagnostic techniques, and aggressive treatment have led to an increase in rare cancers.

CANCER EPIDEMIOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Host-Related Factors in the Interplay among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians

Lorenzo Ruggieri, Anna Moretti, Rossana Berardi, Maria Silvia Cona, Davide Dalu, Cecilia Villa, Davide Chizzoniti, Sheila Piva, Anna Gambaro, Nicla La Verde

Summary: A significant proportion of early breast cancer patients experience medium-term and late distant recurrence. The delayed manifestation of metastatic disease is known as dormancy, characterized by the clinical latency of isolated metastatic cancer cells. The regulation of dormancy involves complex interactions between disseminated cancer cells and their microenvironment, influenced by inflammation and immunity. This review aims to provide a useful tool for physicians and oncologists to understand the clinical implications of cancer dormancy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Medicine, Research & Experimental

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab

Domenico Mallardo, Ester Simeone, Lucia Festino, Marilena Tuffanelli, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Mariaelena Capone, Gabriele Madonna, Francesca Sparano, Eleonora Cioli, Luigi Scarpato, Marco Palla, Rossella Di Trolio, Paolo Meinardi, Corrado Caraco, Gerardo Ferrara, Paolo Muto, Ernesta Cavalcanti, Paolo Antonio Ascierto

Summary: This study investigated the prognostic significance of IL-6 serum levels before and during cemiplimab immunotherapy in patients with advanced cutaneous squamous cell carcinoma. The results showed that high IL-6 levels were associated with poorer survival and shorter progression-free survival. Additionally, patients whose IL-6 levels increased after treatment had a worse response to immunotherapy compared to those with reduced or stable levels.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

添加到收藏夹

Article Multidisciplinary Sciences

The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers

Annalisa Trama, Lisa Licitra, Stefano Cavalieri, Simone Bonfarnuzzo, Paolo Baili, Antonio Ciarfella, Pablo Parente, Giovanni Almadori, Mohssen Ansarin, Almalina Bacigalupo, Philipp Baumeister, Bertrand Baujat, Paolo Bossi, Elisa Cavalera, Maria Cecilia Cercato, Francois Dieleman, Nicolas Fakhry, Virginia Ferraresi, Francesca Gaino, Danilo Galizia, Jana Halamkova, Elina Halme, Jose Hardillo, Benedikt Hofauer, Emma Kinloch, Lorenzo Livi, Laura Deborah Locati, Stefan Mattheis, Giuseppe Mercante, Aurora Mirabile, Gabriele Molteni, Ester Orlandi, Roberto Persio, Stefania Sciallero, Ludi Smeele, Marta Tagliabue, Valentino Valentini, Carla Van Harpen, Christoph Benedikt Westphalen, Laura Botta

Summary: The study highlights the importance of establishing clinical registries within networks specializing in rare cancers. The EURACAN registry focuses on rare head and neck cancers, aiming to investigate their natural history, prognostic factors, treatment effectiveness, and quality of care indicators. Data will be collected from hospitals with expertise in head and neck cancers, and statistical analysis will be conducted to identify independent predictors and evaluate treatment outcomes.

PLOS ONE (2023)

添加到收藏夹

Article Oncology

Cancer treatment data available in European cancer registries: Where are we and where are we going?

Francesco Giusti, Carmen Martos, Annalisa Trama, Manola Bettio, Arantza Sanvisens, Riccardo Audisio, Volker Arndt, Silvia Francisci, Carine Dochez, Josepa Ribes, Laura Pareja Fernandez, Anna Gavin, Gemma Gatta, Rafael Marcos-Gragera, Yolande Lievens, Claudia Allemani, Roberta De Angelis, Otto Visser, Liesbet Van Eycken

Summary: Population-based cancer registries are responsible for collecting data on cancer incidence and survival. The role of cancer registries has expanded to include studies on cancer prevention and quality of care. However, there is still variation in collecting treatment data in Europe.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype

Aldo Caltavituro, Roberto Buonaiuto, Erica Pietroluongo, Rocco Morra, Fabio Salomone, Pietro De Placido, Martina Pagliuca, Angelo Vaia, Margaret Ottaviano, Marianna Tortora, Sabino De Placido, Giovannella Palmieri, Mario Giuliano

Summary: Sarcomas of the thoracic cavity are rare and heterogeneous, with Ewing Sarcoma being a rare finding in this location. Current management often requires a multidisciplinary approach, but long-term outcomes remain poor.

BIOMEDICINES (2023)

添加到收藏夹

Article Medicine, Research & Experimental

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

Domenico Mallardo, Mario Fordellone, Andrew White, Margaret Ottaviano, Francesca Sparano, Michael Bailey, Arianna Bianca Facchini, Sufey Ong, Piera Maiolino, Corrado Caraco, Sarah Church, Ernesta Cavalcanti, Sarah Warren, Alfredo Budillon, Alessandra Cesano, Ester Simeone, Paolo Chiodini, Paolo Antonio Ascierto

Summary: This retrospective study explored the role and timing of neutrophil/lymphocyte ratio (NLR) as a potential biomarker of response in patients with metastatic melanoma. Transcriptomic gene analysis revealed that high baseline NLR is associated with inflammation and tumorigenesis, while low baseline NLR is linked to immune activation. These findings suggest that NLR could serve as a potential biomarker for treatment strategy guidance in metastatic melanoma patients.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

添加到收藏夹

Article Oncology

Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study

Federica Pecci, Luca Cantini, Valeria Cognigni, Fabiana Perrone, Giulia Mazzaschi, Veronica Agostinelli, Giulia Mentrasti, Elda Favari, Michele Maffezzoli, Alessio Cortellini, Francesca Rossi, Rebecca Chiariotti, Francesco Maria Venanzi, Giuseppe Lo Russo, Giulia Galli, Claudia Proto, Monica Ganzinelli, Francesca Tronconi, Francesca Morgese, Carla Campolucci, Marco Moretti, Arianna Vignini, Marcello Tiseo, Roberta Minari, Marco Luigi Bruno Rocchi, Sebastiano Buti, Rossana Berardi

Summary: This study retrospectively collected lipid profile data of patients with solid cancer treated with ICIs and found that cholesterol and triglycerides play different roles in predicting clinical outcomes. A lipid score was developed to stratify patients into different subgroups, which was associated with survival in patients.

ONCOLOGIST (2023)

添加到收藏夹

Article Medicine, General & Internal

Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine

Zelmira Ballatore, Francesco Bozzi, Sara Cardea, Francesco Domenico Savino, Antonella Migliore, Valentina Tarantino, Natalia Chiodi, Elisa Ambrosini, Francesca Bianchi, Gaia Goteri, Alessandra Filosa, Francesca Barbisan, Elisa Bartoli, Roberto Papa, Rossana Berardi

Summary: The study aims to personalize treatment approaches for metastatic cancer patients by using molecular profiling to determine precise medical goals and promote targeted therapy strategies among patients. Through collaboration in the Molecular Tumour Board, we have successfully established a multidisciplinary team in Italy that provides personalized treatment recommendations to referred patients using molecular testing.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Oncology

Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study

Stefania Gori, Alessandra Fabi, Catia Angiolini, Monica Turazza, Piermario Salvini, Gianluigi Ferretti, Elisabetta Cretella, Lorenzo Gianni, Claudia Bighin, Angela Toss, Claudio Zamagni, Patrizia Vici, Costanza De Rossi, Antonio Russo, Giancarlo Bisagni, Antonio Frassoldati, Lucia Borgato, Anna Cariello, Claudia Cappelletti, Roberto Bordonaro, Saverio Cinieri, Alessandra Modena, Matteo Valerio, Maria Francesca Alvisi, Irene De Simone, Francesca Galli, Eliana Rulli, Anna Santoni, Fabrizio Nicolis

Summary: This study evaluated the rate of early breast cancer patients treated with neoadjuvant systemic therapy in Italy. It found that 13.9% of patients received this treatment. Various factors such as menopausal status, tumor size, lymph node involvement, grade, HER2 status, and triple negative subtype were associated with the decision to administer neoadjuvant therapy. The choice of therapy also varied based on the patient's phenotype subgroup.

CANCERS (2023)

添加到收藏夹

Review Medicine, General & Internal

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?

Luca Urso, Luca Filippi, Angelo Castello, Maria Cristina Marzola, Mirco Bartolomei, Corrado Cittanti, Luigia Florimonte, Massimo Castellani, Paolo Zucali, Alessio Bruni, Roberto Sabbatini, Massimo Dominici, Stefano Panareo, Laura Evangelista

Summary: PSMA ligand PET has higher detection rates compared to conventional imaging in CRPC patients, reducing the number of M0 CRPC patients. However, its impact on patients' prognosis is still uncertain. Additionally, PSMA ligand PET has sensitivity and specificity limitations in CRPC patients.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.